for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ファイザー・インク

PFE.N

現在値

36.55USD

変化

0.07(+0.19%)

出来高

7,153,002

本日のレンジ

36.26

 - 

36.83

52週レンジ

27.89

 - 

43.02

∙ 約20分前の相場を表示しています。

適時開示

Canada says Pfizer to slow deliveries of COVID-19 vaccines - procurement minister

Jan 15 (Reuters) - Canada's Procurement Minister Anita Anand says::PFIZER WILL TEMPORARILY SLOW DELIVERIES OF VACCINE DUE TO PRODUCTION PROBLEMS FOR ALL COUNTRIES SUPPLIED BY ITS EUROPEAN FACTORY .CANADA STILL WILL BE ABLE TO REACH GOAL TO OFFER VACCINATIONS TO ALL CANADIANS BY END OF SEPT .PFIZER PRODUCTION DELAY IS DUE TO WORK EXPANDING MANUFACTURING CAPACITY AND IS TO BE EXPECTED WHEN GLOBAL SUPPLY CHAINS ARE STRETCHED WELL BEYOND LIMITS . (Reporting by Steve Scherer). ((Steve.Scherer@thomsonreuters.com;)).

EMA Says To Evaluate Safety Reports Of COVID-19 Vaccines From January

Jan 15 (Reuters) - European Medicines Agency (EMA): :STARTING THIS MONTH, EMA’S SAFETY COMMITTEE (PRAC) TO EVALUATE SAFETY REPORTS SUBMITTED BY MARKETING AUTHORISATIONS HOLDERS OF COVID-19 VACCINES.PFIZER IS EXPECTED TO SUBMIT THEIR MONTHLY SUMMARY SAFETY REPORT IN MID-JANUARY.FIRST SUCH REPORT WILL BE FOR COMIRNATY.MONTHLY SUMMARY SAFETY REPORT WILL INCLUDE INFORMATION ON REPORTED SUSPECTED ADVERSE REACTIONS, INCLUDING ADVERSE EVENTS OF SPECIAL INTEREST.

Pfizer’s Xalkori Approved By FDA For ALK-Positive Anaplastic Large Cell Lymphoma

Jan 14 (Reuters) - Pfizer Inc <PFE.N>::PFIZER’S XALKORI® (CRIZOTINIB) APPROVED BY FDA FOR ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IN CHILDREN AND YOUNG ADULTS.PFIZER INC - FDA APPROVAL IS BASED ON RESULTS FROM STUDY ADVL0912.

Biontech SE says In Talks With EC About Amendment To Existing Supply Agreement For Comirnaty

Jan 8 (Reuters) - BioNTech SE <22UAy.DE>::BIONTECH SE - IN TALKS WITH EC ABOUT AMENDMENT TO EXISTING SUPPLY AGREEMENT FOR COMIRNATY, THE PFIZER-BIONTECH COVID-19 VACCINE.BIONTECH SE - ADDITIONAL DOSES OF PFIZER-BIONTECH COVID-19 VACCINE WOULD BE DELIVERED TO EU STARTING IN Q2 OF 2021.

Pfizer Says Its Investigational Antiviral For COVID-19 Is Currently In Clinical Trials - Tweet

Jan 8 (Reuters) - :PFIZER SAYS ITS INVESTIGATIONAL ANTIVIRAL FOR COVID-19 IS CURRENTLY IN CLINICAL TRIALS.

EMA Says CHMP Recommends Updating Product Information For Pfizer's Comirnaty Vaccine

Jan 8 (Reuters) - EMA::EMA SAYS EXTRA DOSE FROM VIALS OF COMIRNATY COVID-19 VACCINE.EMA- EMA'S HUMAN MEDICINES COMMITTEE (CHMP) RECOMMENDED UPDATING PRODUCT INFORMATION FOR COMIRNATY TO CLARIFY THAT EACH VIAL CONTAINS 6 DOSES OF VACCINE.EMA - IF AMOUNT OF PFIZER VACCINE REMAINING IN VIAL AFTER 5TH DOSE CANNOT PROVIDE FULL DOSE (0.3 ML), HEALTHCARE PROFESSIONAL MUST DISCARD VIAL, ITS CONTENTS.EMA - THERE SHOULD BE NO POOLING FROM MULTIPLE VIALS TO MAKE UP A FULL DOSE, AND ANY UNUSED VACCINE SHOULD BE DISCARDED 6 HOURS AFTER DILUTION.

Pfizer Says In Talks With EU Over Addl Vaccine Supplies

Jan 8 (Reuters) - Pfizer Inc <PFE.N>::PFIZER SAYS WE ARE IN TALKS WITH EUROPEAN COMMISSION ABOUT AMENDMENT TO EXISTING SUPPLY AGREEMENT FOR PFIZER-BIONTECH COVID-19 VACCINE COMIRNATY.PFIZER SAYS IN TALKS WITH EU OVER FIRM ORDER FOR ADDITIONAL 200 MILLION DOSES OF COMIRNATY TO BE SUPPLIED TO 27 EU MEMBER STATES, WITH OPTION FOR ADDITIONAL 100 MILLION DOSES.PFIZER SAYS AMENDMENT WOULD ADD TO 300 MILLION DOSES ALREADY COMMITTED TO EU FOR 2021.PFIZER SAYS THIS WOULD BRING TOTAL DELIVERY OF DOSES TO EU MEMBER STATES BY END-2021 TO 500 MILLION, PLUS 100 MILLION DOSES IF EU EXERCISES OPTION.Further company coverage: PFE.N. ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).

Imaginab Says License And Supply Agreement With Pfizer For CD8 ImmunoPET Technology

Jan 7 (Reuters) - ImaginAb Inc::IMAGINAB ANNOUNCES LICENSE AND SUPPLY AGREEMENT WITH PFIZER FOR CD8 IMMUNOPET TECHNOLOGY.IMAGINAB- UNDER TERMS OF DEAL, IMAGINAB WILL SUPPLY CLINICAL DOSES OF 89ZR CD8 IMMUNO-PET AGENT TO PFIZER FOR USE IN SELECT ONCOLOGY CLINICAL TRIALS.IMAGINAB- IMAGINAB WILL RECEIVE LICENSE FEES AND PAYMENTS FOR MANUFACTURING AND OTHER SUPPORT.

Dewpoint Announces Collaboration With Pfizer To Develop Potential Therapies For Rare Form Of Muscular Dystrophy

Jan 6 (Reuters) - Pfizer Inc <PFE.N>::DEWPOINT ANNOUNCES COLLABORATION WITH PFIZER TO DEVELOP POTENTIAL THERAPIES FOR A RARE FORM OF MUSCULAR DYSTROPHY.DEWPOINT - WILL RECEIVE UPFRONT PAYMENT AND WILL BE ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT, AND SALES MILESTONES PAYMENTS, TOTALING UP TO $239 MILLION.DEWPOINT- WILL ALSO BE ELIGIBLE TO RECEIVE ROYALTIES ON ANY APPROVED PRODUCTS.

FDA Statement On Following The Authorized Dosing Schedules For COVID-19 Vaccines

Jan 4 (Reuters) - :FDA STATEMENT ON FOLLOWING THE AUTHORIZED DOSING SCHEDULES FOR COVID-19 VACCINES.FDA SAYS "TWO DIFFERENT MRNA VACCINES HAVE NOW SHOWN REMARKABLE EFFECTIVENESS OF ABOUT 95% IN PREVENTING COVID-19 INFECTION IN ADULTS".FDA - "SUGGESTING CHANGES TO THE FDA-AUTHORIZED DOSING OR SCHEDULES OF THESE VACCINES IS PREMATURE AND NOT ROOTED SOLIDLY IN THE AVAILABLE EVIDENCE".FDA - AVAILABLE DATA CONTINUE TO SUPPORT THE USE OF TWO SPECIFIED DOSES OF EACH AUTHORIZED VACCINE AT SPECIFIED INTERVALS.FDA-FOR PFIZER-BIONTECH VACCINE, INTERVAL IS 21 DAYS BETWEEN 1ST & 2ND DOSE; FOR MODERNA COVID-19 VACCINE, INTERVAL IS 28 DAYS BETWEEN 1ST & 2ND DOSE.FDA- "WHAT WE HAVE SEEN IS THAT THE DATA IN THE FIRMS’ SUBMISSIONS REGARDING THE FIRST DOSE IS COMMONLY BEING MISINTERPRETED".FDA- UNTIL VACCINE MAKERS HAVE DATA SUPPORTING CHANGE, WE CONTINUE TO STRONGLY RECOMMEND HEALTH CARE PROVIDERS FOLLOW FDA-AUTHORIZED DOSING SCHEDULE.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up